Status:
COMPLETED
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
Lead Sponsor:
Hugel
Conditions:
Crow's Feet Lines
Eligibility:
All Genders
19-65 years
Phase:
PHASE3
Brief Summary
To determine the efficacy and safety of Botulax® in treatment of crow's feet line
Detailed Description
1. Allocation: Randomized 2. Masking: Double Blind
Eligibility Criteria
Inclusion
- Male or female of at least 19 to 65 years old
- Bilaterally symmetrical moderator-to-severe CFL at maximum smile on the FWS as rated by the investigator
Exclusion
- Subject with hypersensitivity to the investigational products or their components
- Female subject who are pregnant or lactating
- Subject who are unable to communicate or follow the instructions
- Subject who are not eligible for this study based on the judgment of an investigator
Key Trial Info
Start Date :
January 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2019
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03408236
Start Date
January 17 2018
End Date
June 7 2019
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hugel
Seoul, South Korea